Zimbabwe has declined a substantial American health deal worth $367m (£272m) over five years over Washington's demand for sensitive information.
The decision came to light following a government memo from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "skewed".
An official representative later explained that the US was demanding access to genetic material for scientific study and commercial purposes but refused to guarantee the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for more dialogue to find a agreement suitable to both sides so the nation's critical HIV programme can be sustained.
Wider Implications
This development follows a comparable situation in Kenya, where a court suspended a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and accountability.
Based on statements, Sixteen nations in Africa have so far agreed to these new agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership might have yielded significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our citizens should a new disease outbreak emerge."
Sovereignty and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting frameworks previously set up via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to ongoing discussions with our US partners on how subsequent collaboration might be structured in a way that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks must proceed considering a large portion of the country's Aids initiatives were funded by international support.
"If technical issues arise, such as those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," the group commented.
The halted deal emphasises the continuing tensions between accepting crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.